Report: Teva changes up leadership of U.S. generics division


JERUSALEM — Teva has shuffled some of its executives in an effort to effectively compete in the U.S. generics market, according to published reports.

The company — which updated its 2012 non-GAAP financial outlook last Thursday to include diluted earnings per share of $5.30 to $5.40, as well as generic product (including API) net sales of approximately $10.7 billion, consisting of U.S. generic sales of $4.6 billion, European generic sales of $3.4 billion, and ROW generic sales of $2.7 billion — said Allan Oberman, who led Teva's EMIA (Eastern Europe, Israel, the Middle East, and Africa) division, now will lead the U.S. generics division, while the division's former leader, Tim Crew, is moving to another role in the organization, according to the Philadelphia Inquirer.

The news comes at the heels of former Bristol-Myers Squibb executive Jeremy Levin taking the reins of the generic drug maker.

Click here to read the full story.

Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

This ad will auto-close in 10 seconds